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ZACHARY T. BLOOMGARDEN
DIABETES, INSULIN, AND
CANCER—At a symposium discussing
controversies pertaining to relationships
between diabetes and cancer, Jeffrey A.
Johnson (Edmonton, Canada) reviewed
epidemiologic data, beginning with a
meta-analysis showing that diabetes is
associated with increased rates of cancers
of the pancreas, colon and rectum, blad-
der, liver, and breast; endometrial cancer;
and non-Hodgkin’s lymphoma. Prostate
cancer rates are decreased, perhaps as a
consequence of a subtle form of hypo-
gonadism, but prostate cancer mortality
is increased among diabetic men who do
develop prostate cancer. Obesity in-
creases the development of cancers as
well,toagreaterdegreewithgreaterlevels
of obesity, particularly for cancers of the
esophagus and thyroid and, among
women, cancers of the endometrium,
gallbladder, colon, and kidney. Cancer
mortality increases by ;50% in both
sexes in association with obesity (1).
The interesting exception to the generally
adverse association of obesity with malig-
nancy is its negative relationship with
lung cancer, with cigarette use the pre-
sumed confounder by its weight-reducing
effect (2).
The mechanism of the relationship
betweendiabetesandcancerhasnotbeen
deﬁned in clinical studies. Johnson’s
meta-analysis of trials of glycemic control
did not show an effect on the risk of de-
veloping malignancy (3). Hyperglycemia
was, however, associated with cancer
mortality in10-yearstudiesof.1million
Korean (4) and .500,000 European (5)
men and women, with the studies con-
trolling for obesity though possibly
reﬂecting a role of hyperinsulinemia. A
role of hyperinsulinemia is further sug-
gested by studies showing association of
C-peptide with colorectal cancer risk
(6,7). Reduced cancer survival seen in in-
dividualswithdiabetes(8)maybe,atleast
to an extent, due to diabetes-related
diseases other than the malignancy itself
(9) or to diabetic individuals having a
lower likelihood of undergoing mam-
mography, resulting in presentation
with later-stage tumors (10). Lower rates
of Pap test screening for cervical cancer
havebeenreportedinobesewhitewomen
(11)—further evidence for the latter ex-
planation.
An important group of studies sug-
gests that sulfonylureas and insulin are
associated with greater likelihood of ma-
lignancy than that seen with metformin
(12,13). Longer duration of insulin treat-
ment is associated with greater likelihood
of malignancy (14). Whether there is a
speciﬁc effect of metformin or a general
effect of improved insulin sensitivity is
not clear, as greater levels of physical ﬁt-
ness are also associated with lower cancer
mortality in diabetic and pre-diabetic in-
dividuals (15).
Derek LeRoith (New York, NY) dis-
cussed the mechanisms of increased risk
ofcancerinobesityandintype2diabetes,
reviewing studies of an insulin-resistant
animal model to ask whether the breast
cancer progression and increased promi-
nence of metastases associated with hy-
perinsulinemia were caused by effects at
the insulin receptor (IR) or the insulin-
like growth factor (IGF)1 receptor. There
are two subtypes of the IR. IR-B is the
metabolic receptor. IR-A may be stimu-
lated either by insulin or by IGF2 and is
found in both fetal tissues and in cancers;
IR-A appeared in LeRoith’ss t u d i e st o
explain insulin’s trophic effects on malig-
nancy. The more aggressive tumor be-
havior and more rapid rate of growth
associated with hyperinsulinemia also may
reﬂect cross-talk between the IR/IGF1R
and an oncogene. Treatment strategies
blocking the IR reduce tumor growth
but worsen hyperinsulinemia, as would
be predicted from the model. Another ap-
proach is to reduce insulin levels. LeRoith
described studies of a b-3 adrenergic
receptor agonist decreasing adipose tis-
sue mass; circulating insulin levels de-
creased with reduction in tumor growth.
He concluded that endogenous hyperin-
sulinemia is an important risk factor for
cancer progression, presumably working
in conjunction with hyperglycemia, with
dyslipidemia, with elevation in levels of a
variety of nutrients, and with the proin-
ﬂammatory state leading to elevations in
IGF1, leptin, cytokines, and chemokines
and reductions in adiponectin—all occur-
ring as a consequence of insulin resistance.
Hyperinsulinemia is, he concluded, one of
many factors in the relationship between
diabetes and malignancy, but he com-
mentedthatitappearstoexplaintheinter-
section ofanumberofrelatedmechanisms
of cancer growth.
John Lachin (Rockville, MD) dis-
cussed what he termed “facts and fancies”
in the understanding of whether there is a
relationship between insulin glargine and
cancer. He cited the Polish-born British
mathematician Jacob Bronowski, who
stated, “All information is imperfect ...
[and] errors are inextricably bound up
with the nature of human knowledge”
(16). The gold standard of medical re-
search is the randomized controlled trial
(RCT), which assures that treatment as-
signment is independent of patient char-
acteristics, eliminating selection bias and
confounding and allowing one to infer a
causal relationship between the outcome
andtheexperimentalvariable.Incontrast,
observational studies have no randomized
control subjects and many potential biases
ofselectionandconfounding.Suchstudies
are necessary in settings where a RCT is
impossible, such as that of cigarette smok-
ing and cancer, but make it difﬁcult to es-
tablish causality. Thus, in analyzing such a
set of observations, one must endeavor to
understand the degree to which an associ-
ation cannot be explained by other factors.
Lachin cited as an example the association
between coffee consumption and cancer,
which has been shown to be confounded
withcigarettesmokingbecausemorecoffee
drinkerssmoke.Onemustinthiscaseusea
regression or stratiﬁcation model, which
requires correct model speciﬁcation and
knowledge of all confounders. Adjustment
then is used to give the likelihood of ad-
verse outcome if the confounder were
imaginedtobeequallydistributedbetween
groups. Lachin pointed out, however, that
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PERSPECTIVES ON THE NEWSnotallcovariateimbalancesintroducebias,
whereas adjustment may itself introduce
bias. An important example is as follows:
if male-female differences were to be ad-
justed for body weight, a bias would be
introduced skewing the female group to
characteristics of heavier women.
Given this background, Lachin asked
to what extent the recent epidemiologic
study suggesting a relationship between
use of insulin glargine and cancer should
be considered to have accurately been
analyzed. Hemkens et al. (17) identiﬁed
127,031 patients exposed for an average
of 1.63 years, 95,804 to human insulin
and 23,855 to insulin glargine, excluding
those using combinations of insulin and
those changing insulin. It was not possi-
ble in the analysis to distinguish type 1
from type 2 diabetes, body weight was
not reported, and the type of malignancy
not reported. With no adjustment, it has
not been widely realized that there was
actually a 16% reduction in risk among
individualsreceivinginsulinglargine.Ad-
justingforageandsexdidnotchangethis.
The insulin dosesgiven to the glargine ver-
sus human insulin groups, however, were
different. When the authors adjusted for
the insulin dose administered, they found a
suggestionthatglargineledtoa14%increase
in risk of malignancy.
Lachin explained that the analysis
used, the Cox proportional hazards
model, is valid only if covariate values
for all subjects are obtained prior to the
time of the event. The study, however,
computed an average insulin dose for
each subject over the entire follow-up,
including the doses administered after
diagnosis of cancer (18). Lachin won-
dered, how could the dose adjustment
lead to a change from 16% less risk
t o1 4 %m o r e ?Al a r g e rn u m b e ro ft h e
glargine-treated individuals must therefore
have received lower, and fewer must have
received higher, doses of insulin. The risk of
cancerincreasedinthesmallgroupofglargine
patients receiving doses of .40 units/day.
“The pivotal question,” Lacher said, “is
whether or not the adjustment in insulin
dose is statistically appropriate.” In multi-
ple RCTs of glargine versus NPH insulin,
therearenegligibledifferencesinthedoses
needed to achieve comparable levels of
glycemic control. What, then, are reasons
for the dose imbalance? It is likely, he sug-
gested,thattherewereunmeasuredpatient
factors differentially distributed between
thegroups,leadingtheglargine-treatedpa-
tients to require lower insulin doses. If
this is the case, it is incorrect to statistically
adjust for confounding by insulin dose be-
cause it introduces the presumed bias of
those between-group differences. Indeed,
there were substantial reasons for the
dose imbalance. The human insulin pa-
tients either received basal insulin alone
or a combination of basal/bolus insulin,
whereas the glargine-treated patients, by
the design of the analysis, only received
the basal insulin. As a consequence, 77%
oftheNPH-treatedbut92%oftheglargine-
treated group received oral agents, sug-
gesting differences in endogenous insulin.
Perhaps there were no type 1 diabetic pa-
tients in the glargine group but were some
in the NPH insulin group. The dataset
available did not allow the authors to ad-
just for such differences. The analysis
without dose adjustment, Lachin said,
would therefore more accurately reﬂect
the effect of glargine in the population,
reﬂecting either a decrease or, at most, no
increase in risk, a ﬁnding conﬁrmed by
other studies. Lachin further suggested
that the glargine-treated patients receiving
higherinsulindoseswerelikelytohavehad
the allocation bias of confounding by indi-
cation or of imbalances in other important
factors, suggesting an issue with cohort se-
lection bias. He concluded that there is no
replicated evidence that glargine at any
dose is associated with increase in risk of
malignancy.
Jay Skyler (Miami, FL) further dis-
cussed lessons from what he called “the
Diabetologia story” of the relationship be-
tween insulin glargine and development
of malignancy, describing “what that
storyactuallywas.”Fourarticlesappeared
in June 2009 (13,17,19,20), along with
a ne d i t o r i a l( 2 1 ) .A tt h es a m et i m e ,t h e
European Association for the Study of
Diabetes issued a press release with the
inﬂammatorytitle“PossibleLinkBetween
Insulin Glargine and Cancer Prompts
UrgentCallforMoreResearch.”Although
in the body of the release, patients were
urged not to abruptly stop treatment,
Skyler wryly pointed out that “it certainly
excites patients,” particularly with multi-
ple news articles and Web sites,including
one with the name “lawsuits.com,” creat-
ing confusion by suggesting that glargine
was in fact shown to have caused cancer.
The sequence related by Edwin Gale,
theeditorofDiabetologia,explained thata
study from Germany was submitted ﬁrst
reporting that patients using higher glar-
gine doses were more likely to develop
cancer (17) and that the other epidemio-
logic studies were then carried out at
the request of the editors of the journal.
Interestingly, in the analysis all-cause mor-
tality was reduced 32% with glargine, a
ﬁnding not highlighted in the news ar-
ticles but presumably of interest to indi-
viduals taking the medication. This study
was then at best difﬁcult to interpret, with
large imbalance in the proportion of pa-
tients given the highest insulin dose,
with a high mean age, and with lack of
information on important covariates.
TheSwedishdatabasecombinedseven
nationwide registries with .114,000 pots,
ﬁnding a neutral effect on all cancers, in-
creased breast cancer risk for glargine
monotherapy but not for glargine in com-
b i n a t i o n ,a n d ,a g a i n ,as i g n i ﬁcantly de-
creased mortality risk with glargine (19).
Theﬁndingswereadjustedformultipleco-
variates, potentially further lessening reli-
ability.
The Scottish database was a nation-
wide diabetes registry that similarly failed
to show an increased risk of all cancers
(20). The study showed a nonsigniﬁcant
increase in breast cancer, although risk
wasincreasedinpatientsreceivinginsulin
glargine alone, based on six events in one
of the two cohorts studied. Skyler noted
that in this cohort, there were 18,455
non–glargine treated versus only 411
glargine-treated patients. The authors ob-
served that the “subgroup effects most
likely reﬂect allocation bias (ie, those less
healthy in many ways being treated with
insulin glargine on its own).” The U.K.
THIN database showed that there was in-
creased risk with sulfonylureas and with
insulin relative to metformin but that
there was no signiﬁcant increase in risk
for insulin glargine either for all cancers
or, in particular, for breast cancer (13).
Skyler concluded, “The hypothesis ...
generated by the German study ... was
ﬂawed.” Although the three additional
studies concluded that there was no evi-
dence that glargine caused cancer, he ob-
served that this “sure doesn’tr e ﬂect those
news headlines, does it?” There was an
additional article in that issue, an analysis
ofanRCTcomparingNPHwithglargine
for retinopathy with a long-duration
follow-up, and there was no signiﬁcant
difference in malignancy (22). A subse-
quent article from the sanoﬁ-aventis data-
base of 26 randomized trials up to 3 years
indurationshowednoevidenceofcancer
(23). “Unsubstantiated, unwarranted,
unproven, that’sm yc o n c l u s i o n , ” said
Skyler.
The Outcome Reduction With Initial
Glargine Intervention (ORIGIN) trial is
underway, with 12,612 randomized to
care.diabetesjournals.org DIABETES CARE, VOLUME 34, JUNE 2011 e101
Bloomgardenglargine versus standard care. A press
release from the data-monitoring com-
mittee on 5 August 2009 stated that with
.50,000 person-years of exposure, there
was “no cause for concern” (24). Skyler
noted that the randomization is to insulin
versus no insulin and may help address
the question of whether exogenous insu-
lin has an adverse effect on malignancy
andwhetherthemetforminversusinsulin
comparison is confounded by different
characteristics of those receiving the dif-
ferent treatments.
What of the suggestion that glargine
has greater IGF-1 receptor binding and
greater mitogenicity? Circulating insulin
levels after glargine administration are
unlikely to reach the levels required to
interact with the IGF1R (25). Further-
more, the glargine M1 metabolite is the
primary circulating insulin component
after injection, and this form has reduced
IGF1R afﬁnity.
What, Skyler asked, of the study of
insulin-treated patients in Florence sug-
gesting that glargine causes increased
malignancy risk (26)? In a study of
1,340 patients with type 2 diabetes start-
ing insulin from 1998–2007, 112 inci-
dent cancer cases were compared with
370 matched control subjects. There
were no signiﬁcant differences between
case and control subjects in the propor-
tionofpatientsexposedtoeachinsulin,but
case subjects had a mean glargine dose of
0.24 units, whereas control subjects used
0.16 units/kg. Incident cancer was associ-
atedwiththeuseof.0.3units/kgglargine.
The case subjects, however, had a higher
comorbidity score, had less retinopathy,
and had a very high cancer incidence—
approximately ﬁvefold greater than in
other Tuscany data.
Several studies at the 70th Scientiﬁc
Sessions of the American Diabetes Asso-
ciation (Orlando, FL) reported further
aspects of the potential relationships
between diabetes, insulin, and cancer.
Chuang et al. (abstract 619) reported
statistically similar malignancy rates of
13.3 vs. 16.4% per 1,000 person-years
andcancerfatalityratesamongthosewith
malignancy of 28 vs. 26%, during 2,472
vs. 3,668 person-years’ follow-up of dia-
betic patients receiving insulin glargine
versushuman insulin,respectively.Nodif-
ferencesincancerriskswerefoundforspe-
ciﬁc different malignancies. Yehezkel et al.
(abstract 620) did report in vitro ﬁndings
that insulin glargine produced atypical
IGF-I receptor internalization and activa-
tion of the Akt and Erk pathways in a colon
cancer–derived cell line. Dankner et al.
(abstract 1144) followed 1,770 nondia-
betic men and women, aged 52 years at
baseline, from 1980 to 2005. Excluding
cancer developing during the ﬁrst 2 years,
results showed that fasting insulin was
not signiﬁcantly associated with total
site-speciﬁc cancer incidence among the
327 individuals developing cancer, but
survival time was 4 years for patients
with cancer whose baseline fasting insulin
was in the upper quartile, which is one-
half that of those in the lower three quar-
tiles,withthehighestquartilehavingasig-
niﬁcant 53% increase in total mortality,
adjusting for age, sex, and ethnicity.
Noto et al. (abstract 1165) performed a
meta-analysis of 22,485 cancer cases
among 250,479 Japanese individuals,
ﬁnding that diabetes increased risk 70%,
with ;3.5-fold greater risk of hepatocel-
lular and endometrial cancers, and some
evidence of increased risk for cancers of
the pancreas, stomach, and lungs.
A Consensus Statement from the
American Diabetes Association and
American Cancer Society conﬁrmed the
association between diabetes and malig-
nancy but concluded that it is unclear
whether the association is related to
hyperglycemia, to insulin resistance, or
to common risk factors such as obesity
(27). It is also unclear whether the asso-
ciationisinﬂuencedbydiabetesduration.
Potential biological links included the
insulin/IGF-1 axis, hyperglycemia, and
chronic inﬂammation. The expert group
considered whether diabetes treatments
inﬂuence risk, offering no recommenda-
tion other than that it is appropriate to
encourage healthy diet, activity, and
weight management.
Should insulin treatment be started
early in the natural history of
diabetes?
Steven Kahn (Seattle, WA) discussed the
concept of insulin treatment at the onset
oftype2diabetes,reviewing“theworking
hypothesis” that this approach preserves
theb-cell,offeringthepotentialtoreverse
diabetes.Astudy usinginsulinto normal-
ize glycemia for 3 weeks carried out more
than twodecadesagoshowedsubsequent
improvement in second-, although not in
ﬁrst-, phase insulin response to intrave-
nous glucose, suggesting improvement in
b-cell function (28).
Freefattyacid(FFA)levelsareelevated
with poor control of diabetes and decline
with improved glycemia; both glucose
and FFA toxicity may then contribute to
abnormal insulin secretion. Kahn dis-
cussedthenotionofglucosetoxicity.There
is a hyperbolic relationship between in-
sulin secretion and sensitivity, which can
beapproximated byanalyzing the relation-
ship between the changeininsulindivided
by the change in glucose following nu-
trientingestion,ameasureofsecretion,and
the reciprocal of fasting insulin, a measure
of sensitivity. The product of the two is
termed the disposition index. In impaired
glucose tolerance (IGT)/impaired fasting
glucose (IFG) and, to a considerably
greater extent, in diabetes, the curve is
shifted downward, with lower disposition
index (29). There is progressive reduction
inthe ﬁrst-phase acute insulin response to
glucoseasIFGprogresses,fromnearlynor-
mal at a fasting glucose of ;100 mg/dL
to less than one-third at ;126 mg/dL
(30). Kahn reviewed an early study with
24-h glucose infusion to raise blood glu-
cose levels from 92 to 115 mg/dL, leading
to increases in insulin levels but actually
with increased insulin sensitivity and an
increased second-phase insulin response
to intravenous glucose. Very short-term
and mild hyperglycemia, then, may not
have adverse effect. A subsequent study
of hyperglycemia sustained at ;160 and
;225mg/dLfor3daysusingvariableglu-
cose infusion showed, however, develop-
ment both of insulin resistance and, at the
higher glucose level, of a progressive de-
crease in the insulin secretory response
(31)—an effect, Kahn commented, that
“takes a lot of glucose and [requires] very
elevated glucose concentrations.” There
are no speciﬁc human data to show we
can reverse this, but administration of
phlorizen to 90% pancreatectomized
rats, lowering blood glucosebyincreasing
glycosuria, restored both the ﬁrst- and
second-phase insulin secretory responses
per residual pancreas mass (32). Kahn
notedthatsuchastudycannowbecarried
out in humans using sodium glucose
transporter-2 inhibitors.
Kahnnextaddressedb-cell lipotoxic-
ity. He discussed a study showing decline
in the acute insulin response to glucose
with increasing FFA levels in relatives of
type 2 diabetic individuals (33). Another
studyshowedthat3daysofFFAelevation
reduced insulin sensitivity, by decreasing
nonoxidative glucose uptake, to levels
similar to those of relatives of type 2 di-
abetic individuals; insulin secretion in-
creased in individuals without a family
history of diabetes, however, while de-
creasing in relatives (34). In contrast, rela-
tives of type 2 diabetic individuals treated
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provement both in insulin sensitivity
and in ﬁrst- and second-phase glucose-
inducedinsulinrelease(35).Interestingly,
although a 24-h glucose infusion given
alone improves both insulin secretion
and sensitivity, when this is combined
with elevations in FFA both insulin sensi-
tivity and b-cell function decrease, sug-
gesting that both glucose and lipotoxicity
play roles in the development of diabetes
(36).
Kahn reviewed a number of potential
mediatorsofthesephenomena.Oxidative
stress is strongly associated with hyper-
glycemia (37) and with elevations in FFA
andreducesinsulingeneexpression,with
improvement seen after antioxidant ad-
ministration (38). Endoplasmic reticu-
lumstress,alsoreferredtoastheunfolded
proteinresponse,isacomplexprocessin-
creased by FFA. Inﬂammation is another
mediator, with evidence of interleukin-
1b expression in type 2 diabetic, but not
controlislets,inducedbyincubationwith
high glucoseconcentrations (39).Finally,
islet amyloid, present in islets of individ-
uals with long-standing type 2 diabetes
(40), offers a pathway independent of ox-
idative stress leading to b-cell damage
(41). The ability of insulin to reduce glu-
cose and FFA may protect against these
harmful effects. An interesting question
is whether insulin may protect the b-cell
independent of the glucose- and FFA-
lowering effects, as suggested by studies
of insulin secretion during infusion of ex-
ogenous B28-Asp insulin, which can be
immunologically distinguished from en-
dogenous insulin (42).
In this context, studies of initial in-
sulin treatment increasing the proportion
of individuals achieving remission of type
2 diabetes suggest a fascinating potential
approach (43). Those patients who failed
to maintain remission had higher fasting
and 2-h glucose and A1C after treatment
and took a longer time to achieve euglyce-
mia, suggesting that a greater underlying
b-cell defect prevented insulin-induced
improvement in b-cell function. Indeed,
Kahn pointed out, in the UK Prospective
DiabetesStudyeuglycemiawasnotachieved
and both metformin and rosiglitazone have
very different effects from glyburide in lead-
ing to more sustained control of glycemia
(44). He suggested that the ability of insulin
toimproveb-cellfunctionismediatedpri-
marily by its ability to reduce glucose and
FFA, that failure to maintain glucose con-
trol is determined in large part by b-cell
function, and that measures decreasing
glucolipotoxicity and/or reducing b-cell
secretory demand appear to prevent pro-
gression of diabetes.
Juliana Chan (Hong Kong, China)
further discussed the Asian data on in-
tensive insulin treatment of early diabetes,
reviewing evidence that both b-cell dys-
function and visceral obesity are associ-
ated with oxidative stress, inﬂammation,
andamylintoxicityanddiscussingstudies
of intensive insulin treatment. Despite
their lower prevalence of obesity, Asians
have higher rates of diabetes than Cauca-
sians (45) and more visceral fat (46). The
China Diabetes Survey, an analysis of
46,239 individuals from 14 provinces,
showed that 25% had diabetes or pre-
diabetes. Chan reviewed results of a
2007 survey done in Singapore, in which
the majority of those with prediabeteshad
IGT, which she suggested indicates a
greater degree of b-cell defect. Reduction
in ﬁrst-phase insulin secretion appears to
characterize Japanese individuals with
prediabetes (47), with decreased insulin
secretion preceding insulin resistance in
this group (48). Among Japanese Ameri-
cans, increased visceral fat and b-cell dys-
function are associated with development
of diabetes (49), with increased body
weight not required for development of
insulin resistance and low BMI with high
waist circumference actually appearing to
be associated with risk of worse glycemic
status as well as with complications such
as nephropathy (50). Chan reviewed her
study showing structural abnormalities
of islets including amyloid inﬁltration, in-
ﬂammation, and apoptosis, seen at au-
topsy of Chinese type 2 diabetic patients
(51),andastudyshowingb-cellstructural
defects and functional abnormalities in
Japanese individuals with diabetes (52).
A study of 136 newly diagnosed
Chinese type 2 diabetic individuals dem-
onstrated recovery of b-cell function after
2 weeks of continuous subcutaneous in-
sulin infusion (CSII) (53). A1C decreased
from 10 to 8.7%, insulin and C-peptide
improvedat allpointsduringIVGTT,and
circulating lipid and proinsulin levels de-
creased, suggesting reduced b-cell stress.
At 3, 6, and 12 months after withdrawal,
approximately 70, 65, and 30% of pa-
tients were in drug-free remission, which
was associated with greater insulin secre-
tionlevels.Thisgroup’ssubsequentstudy
of382individualsaged25–70years,from
nine centers in China and carried out
from 2004 to 2006, randomized patients
to CSII or multiple dose insulin (MDI),
beginning with a 0.5 units/kg insulin
dose, or to oral hypoglycemic agent treat-
mentwithsulfonylureasand/ormetformin,
for2weeks,withsubsequentfollow-upon
diet and exercise alone (42). Remission at
2weekswasdeﬁnedbyFBG,112and2-h
glucose ,144 mg/dL, while relapse was
deﬁned by levels .126 and 180 mg/dL,
respectively. Euglycemia was achieved in
4daysin97%ofthoseonCSII,in5.6days
in 95% with MDI, and in 9.3 days in 84%
with oral agents at daily insulin doses of
0.68 and 0.74 units/kg and mean glicla-
zide and metformin doses of 180 and
1,000 mg daily in the respective groups.
Hypoglycemia was seen in 31, 28, and
19%, and remission was maintained at
1 year in 51, 45, and 27%, respectively.
The acute insulin response improved after
insulin treatment, whereas the 1-year
decline in b-cell function was greater
withoralagents.Thelikelihoodofrelapse
increased with higher fasting glucose
levels.
Several similar studies of intensive
insulintreatmenthave been carriedout in
Asia in patients with longer duration of
type 2 diabetes. In Korea, 34% of 91 type
2 diabetic patients achieved remission
with CSII after an average of 54 days of
treatment, lasting 14 months; responders
had had shorter diabetes duration, higher
C-peptide and lower postprandial glu-
cose levels and tended to be more obese
and have fewer complications; responders
rapidly reduced their insulin require-
ment (54). In Taiwan, 50 patients were
randomized to a 6-month course of MDI
or to oral agents after all had a 10–14 day
intensive inpatient basal-bolus treatment;
A1C levels were 6.3 vs. 7.5%, respec-
tively, at 6 months and 6.8 vs. 7.8% at
12 months (55). Even longer periods of
C S I Im a yb eu s e f u l ,w i t ha3 0 - m o n t h
study in 15 patients with long-standing
diabetes showing improvement in dys-
lipidemia and reduction in levels of in-
ﬂammatorymarkers(56).IntheKumamoto
study,6yearsofintensiveinsulintreatment
decreased microvascular complications
by 70% in 110 lean Japanese patients
(57). Chan concluded that Asians have a
dual defect leading to diabetes, with both
reduced b-cellreserveandvisceralobesity
contributingtothediabetesepidemic,and
that there is considerable phenotypic and
genotypic heterogeneity but that short-
term CSII induces diabetes remission
and restores b-cell function, particularly
in patients with short duration, and that
both short- and long-term intensive insu-
linadministrationreducesgluco-andlipo-
toxicity, suggesting the importance of
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treatment in these populations. Mayer
Davidson (Los Angeles, CA), asked, “Is it
really worth all the hassles of starting in-
sulin just for 6 to 12 months’ remission?”
Chan agreed that the cost-effectiveness of
this treatment needs to be studied, prefer-
ably over a long-term period to determine
whether sustained beneﬁt of the interven-
tion can be demonstrated.
Hertzel Gerstein (Hamilton, Ontario,
Canada)discussedearlyinsulintreatment
of type 2 diabetes, asking, “How early is
early?” What, he asked, does a high glu-
cose or A1C mean? At what glucose/A1C
levels do problems develop? How are
glucose/A1C levels controlled? Do any
existing trials provide clues? And, ﬁnally,
what will we learn from the ongoing
ORIGIN trial?
In a meta-analysis of the relationship
between fasting glucose concentration
and vascular disease, with 8.5 million
person-years of follow-up, the level that
should be considered normal fasting
glucose in terms of vascular risk, even
with advanced diabetes, is 90–95 mg/dL
(58).“Thekey tomaintaining that normal
fasting glucose is the pancreas and its in-
sulin secretion,” Gerstein said, implying
that “the best test of the b-cell is your
glucose level.” His meta-analysis of pro-
spective studies showed that IGT is as-
sociated with a 2.5-fold higher risk of
nonfatal CVD and a 1.5-fold higher risk
of mortality and that fasting glucose
.110mg/dLwithoutelevationin2-hglu-
cose was associated with 20, 28, and 21%
increases in risks of myocardial infarction,
nonfatal CVD, and mortality, respectively
(59). Fasting glucose .100 mg/dL was,
adjusted for age, cigarettes, BMI, and
blood pressure, associated with 7 and 15%
increases in cardiovascular risks in men and
in women, respectively (57). “Categories of
increased glucose that are clearly not dia-
betic,” Gerstein stated, “carry increased
risk,” with coronary mortality beginning
to increase at fasting glucose levels of ;95
mg/dL. In the 33-year follow-up of the
Whitehall study, glucose levels measured
2 h after 50 g oral glucose showed a contin-
uous relationship with coronary mortality
beginning at 83 mg/dL; mortality increased
22% for every 18 mg/dL increase up to 200
mg/dL (60), leading to the notion of “ac o n -
tinuum of dysglycemia.” Similar analysis
withA1C shows an18% increaseinmortal-
ity risk for every 1% increase, “extending
right into the normal range” as well (61).
Diabetes is typically diagnosed ;5
years after its onset, Gerstein observed.
“How,” he asked, “do we clinically control
glucose levels?” Diet and weight loss,
physical activity, metformin, and thiazoli-
dinediones increase the effect of available
insulin; sulfonylureas, glinides, incretins,
and insulin itself increase the supply of
insulin; and a-glucosidase inhibitors, in-
cretins, and pramlintide reduce the need
for rapid insulin supplies. All therapies for
diabetes, then, can be viewed through the
vantage point of mediation by insulin. In
the UK Prospective Diabetes Study, newly
diagnosed type 2 diabetic patients treated
with insulin had a 12% reduction in
diabetes-related end points, a 25% reduc-
tioninmicrovasculardisease,and33%re-
ductioninalbuminuriaat12years(62).At
follow-up 10 years later, there was still a
24% reduction in microvascular disease
and there were 15 and 13% reductions
in myocardial infarction and mortality, re-
spectively (63). This, Gerstein said, “sup-
ports the hypothesis that there may very
wellbeaplaceforearlyinsulinuse.”There
isnomaximumorminimuminsulindose,
it is easily titrated, there are no contrain-
dications or drug interactions, there are
easy-to-use insulin delivery devices and
preparations, often only one daily dose is
needed, and we have 88 years’ experience
with it. Might excess glucose-lowering
cause harm, particularly with hypoglyce-
mia? This may be less frequent when
insulin is used early. Questions as to ex-
ogenous insulin being atherogenic, as to
risk of weight gain, and as to carcinoge-
nicity have been raised. At present, no
real evidence exists either for or against
these points.
In the ORIGIN trial of individuals
aged$50yearswithevidenceofCVDand
either IFG/IGT or early diabetes, insulin
glargine, given with a fasting glucose tar-
get of ,95 mg/dL, is being compared
with standard approaches to dysglyce-
mia; the trial is being carried out as a
2 3 2 study, with randomization to an
omega-3 polyunsaturated fatty acid sup-
plement as well (64). Individuals (n 5
12,612) from North and South America,
Europe,India,theAsia/Paciﬁcregion,and
Australia were randomized through De-
cember 2005, with results to be reported
in2012.Theirmeanagewas64years,35%
are female, 12% smoked cigarettes, and
86% had hypertension, 70% dyslipidemia,
66% prior CVD, and 82% diabetes. Base-
line BMI was 29.8 kg/m
2 and A1C 6.5%.
The coprimary outcomes are cardiovascu-
lar death, nonfatal myocardial infarction,
stroke,revascularization,orcongestiveheart
failure. Cognitive function, bone density,
continuous glucose monitoring, weight
status, and glycemia will be followed as
well. Reducing b-cell demand with thiazo-
lidinediones and metformin has greater
effect on b-cell failure than sulfonylureas,
and in those with prediabetes another out-
come being studied is diabetes prevention.
“The notion that using insulin early may
have beneﬁt,” Gerstein concluded, is more
than 50 years old, dating to Banting’sN o b e l
lecture in 1935.
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